Last reviewed · How we verify
Azelastine-Fluticasone Nasal
Azelastine blocks histamine receptors to reduce allergic inflammation, while fluticasone suppresses immune response via glucocorticoid receptor activation in the nasal cavity.
Azelastine blocks histamine receptors to reduce allergic inflammation, while fluticasone suppresses immune response via glucocorticoid receptor activation in the nasal cavity. Used for Allergic rhinitis.
At a glance
| Generic name | Azelastine-Fluticasone Nasal |
|---|---|
| Also known as | Dymista |
| Sponsor | University of Dundee |
| Drug class | Antihistamine/Intranasal corticosteroid combination |
| Target | H1 receptor (azelastine); Glucocorticoid receptor (fluticasone) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Azelastine is a selective H1-receptor antagonist that prevents histamine-mediated allergic symptoms. Fluticasone is an intranasal corticosteroid that reduces inflammatory cell recruitment and cytokine production. Together, they provide dual anti-allergic and anti-inflammatory effects for nasal allergy symptoms.
Approved indications
- Allergic rhinitis
Common side effects
- Headache
- Nasal irritation
- Bitter taste
- Epistaxis
Key clinical trials
- INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION (PHASE4)
- Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (PHASE4)
- Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray
- Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis (PHASE4)
- Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray (PHASE1)
- Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azelastine-Fluticasone Nasal CI brief — competitive landscape report
- Azelastine-Fluticasone Nasal updates RSS · CI watch RSS
- University of Dundee portfolio CI